Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol thorough QT crossover study in healthy men
NL-OMON49378Active, not recruiting
- Sponsor
- Orphazyme A/S
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of arimoclomol in protein aggregation diseases (PAD), lysosomal storage disease (LSD) and muscle diseases (NMD) (3 arms), sponsored by Orphazyme A/S. Primary endpoints: Placebo-corrected change-from-baseline QTcF, AUC0-inf of arimoclomol, M2 and M105 and 12 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
arimoclomol
03
Conditions
protein aggregation diseases (PAD)lysosomal storage disease (LSD)muscle diseases (NMD)
Beyond the preview
Go deeper on NL-OMON49378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49378.